Is Corvus Pharmaceuticals (CRVS) A Bargain After Its Soquelitinib Data Publication?

Corvus Pharmaceuticals (CRVS) drew fresh investor attention after publishing peer reviewed final Phase 1/1b data on its oral ITK inhibitor soquelitinib in Blood, which highlighted durable clinical responses in advanced T cell lymphomas.

The publication arrives after a strong run in Corvus Pharmaceuticals stock, with a 30 day share price return of 6.79% and a 90 day share price return of 21.13% building on a year to date share price return of 93.44% and a very large 3 year total shareholder return. At a latest share price of US$14.16, the stock’s 1 year total shareholder return of 146.69% suggests momentum has been building over time rather than fading, even with a 1 day share price decline of 3.80% as investors digest the latest clinical update.

Capitalize on Corvus Pharmaceuticals momentum in oncology by reviewing a curated set of late stage and high potential biotech stocks in our 19 high quality undiscovered gems.

After such a sharp multiyear rerating of Corvus Pharmaceuticals stock, the real tension now lies between the late-stage promise of soquelitinib and the price already attached to that story. Does the current valuation still leave enough upside for new buyers?

Most Popular Narrative: 59.5% Undervalued

At a last close of $14.16 versus a narrative fair value of $35, Corvus Pharmaceuticals is framed as deeply undervalued with a long runway of potential catalysts still ahead.

The growing use of targeted therapies in atopic dermatitis, alongside continued unmet need in patients who have already tried Dupixent or JAK inhibitors, positions soquelitinib’s differentiated mechanism to potentially address a harder to treat segment of the market. This could support future revenue if efficacy in prior systemic therapy failures is confirmed.

Read the complete narrative.

Want to see what underpins that gap between price and fair value? The narrative focuses on assumptions about future revenue ramps, margin expansion and a rich earnings multiple. Curious how those ingredients combine into a $35 view and a high implied valuation multiple on 2029 earnings?

Result: Fair Value of $35 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Corvus Pharmaceuticals story still hinges on successful soquelitinib data and timely funding, so trial setbacks or dilutive capital raises could quickly challenge this optimism.

Find out about the key risks to this Corvus Pharmaceuticals narrative.

Another view on Corvus Pharmaceuticals valuation

The narrative fair value points to Corvus Pharmaceuticals as undervalued, yet the market is also assigning a rich P/B of 5.3x compared with 2.5x for the broader US Biotechs industry and around 9x for closer peers. That mix of premium pricing and bullish narrative leaves a real question: Is this still mispriced or has optimism already been baked in?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Does the Corvus Pharmaceuticals story feel balanced between promise and risk to you, or slightly tilted to one side? Check the underlying data now and weigh both the upside potential and the open questions by reviewing the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Corvus Pharmaceuticals?

If Corvus Pharmaceuticals has sparked fresh thinking about your portfolio, do not stop here. Use the Simply Wall St Screener to uncover other focused opportunities that might fit your goals.

• Target potential mispricings by scanning for quality companies that still trade below their estimated worth through the 45 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with robust payout profiles using the 12 dividend fortresses.
• Reduce portfolio shocks by prioritising companies with healthier finances through the 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com